Dr. Estela Rodriguez (@Latinamd) header
Dr. Estela Rodriguez (@Latinamd) profile picture

Associate Director Community Outreach- 🫁Thoracic Oncology, University of Miami @SylvesterCancer , 🇵🇷Boricua, Co-founder @KidsHelpingKidsSucceed

Miami, FL
Joined June 2012
Photo by Dr. Estela Rodriguez (@Latinamd)Photo by Dr. Estela Rodriguez (@Latinamd)Photo by Dr. Estela Rodriguez (@Latinamd)Photo by Dr. Estela Rodriguez (@Latinamd)Photo by Dr. Estela Rodriguez (@Latinamd)Photo by Dr. Estela Rodriguez (@Latinamd)Photo by Dr. Estela Rodriguez (@Latinamd)Photo by Dr. Estela Rodriguez (@Latinamd)
At MaTOS Lung 2026, every conversation has a purpose. Leading experts in lung cancer are coming together to share emerging clinical evidence, discuss evolving treatment strategies, and explore new approaches that can help shape better care for patients. The value of this meeting goes beyond the sessions. It is about exchanging perspectives, challenging current thinking, and bringing meaningful clinical insights back into practice. Because progress in lung cancer care depends on continued learning, collaboration, and a shared commitment to improving outcomes. United in Every Breath. #MaTOS #MaTOSLung #UnitedInEveryBreath #LungCancer #ThoracicOncology #OncologyEducation #MedicalEducation #ClinicalInsights #CancerCare #PatientCare @DasMillie11 @delvysra @DDoroshow @lungoncdoc @BalazsHalmosMD @WadeIams @ReckampK @yyelamin @JustinGainor @NaglaAKarimMD @LauraAlderMD @LindaMThoracic @BenCreelan @triparnasen @DCarboneMD @luisraezmd @md_hsu @Joshua_Reuss @lexiuning @Latinamd @drshieldsmd @SCLCSMASHERS @CoreyLanger @EddieSantosMD @collin_blakely @ShirishGadgeel @christine_lovly @chulkimMD @MattGubensMD @hosseinborghaei @StephenVLiu @iyengarpuneeth @ChaftJamie @maryjofidlermd @BRicciutiMD @MNagasaka
8
11
359
#MaTOS26 Dr. Tina Cascone @UTMDAnderson, the reigning queen 👑 of perioperative chemo-IO, takes the stage and makes a compelling case in the debate on ctDNA in early-stage lung cancer (against @HosseinBorghaei) for surveillance , clinical trial integration, and guiding treatment escalation or de-escalation. 🔥 #LCSM
2
5
165
So happy to see Dr. @MPatriciaRivera again at #MaTOS26 ! ❤️ She is one of the @LatinasInMed leaders I truly admire and feel fortunate to know. Her leadership, passion, and dedication to advancing lung cancer screening and addressing barriers to care continue to inspire me. Grateful for her friendship and for the example she sets for all of us. #WomenInMedicine #LCSM #WomeninThoracicMedicine #WomenLead #SheforShe
1
15
356
#MaTOS26 Dr. Jay Lee @UCLAHealth reviews perioperative chemo-IO and survival outcomes in resectable NSCLC. The shift to induction therapy has happened. What’s missing? ▶️Identifying who benefits most, ▶️isolating the adjuvant contribution, and ▶️personalizing surgery vs. chemoradiation in borderline cases #LCSM
1
94
Should lung cancer surveillance stop at 5 years? New data from a Korean population based cohort ( 55K patients) suggest otherwise. Continued CT surveillance beyond 5 years was associated with a 34% lower all-cause mortality rate (2.62% vs. 4.33% annually), 👉🏽highlighting the importance of detecting late recurrences and second primary lung cancers. #LCSM Chest CT Receipt Beyond 5 Years After Lung Cancer Diagnosis and Survival via @JAMAOnc jamanetwork.com/journals/jam…
85
Dr. Estela Rodriguez retweeted
Should all pts get NGS even for early stage NSCLC? @LudaBazhenovaMD leads a panel on perioperative NGS #MaTOSLung2026 w/ @JDoningtonmd @Fred_Hirsch @WadeIams @KHigginsMD @LatinaMD @RachelSanbornMD
1
1
185
No one facing cancer should have to worry about where their next meal will come from. You can help keep nutritious food on the table for Sylvester patients and their families. In just over a year, our food pantry has supported more than 500 patients and distributed more than 1,400 bags of groceries to patients and families. This year, the number of patients we serve each week has doubled. Your gift will help us reach our goal as we work to expand food assistance to our Kendall and Plantation locations, bringing groceries closer to where more patients receive care. Donate today: spr.ly/6018BywOti. #GiveMiamiDay
4
6
226
#MaTOS26 @MPatriciaRivera @UofR makes the case that the future of lung cancer screening lies in a more personalized approach integrating clinical risk assessment and blood-based biomarkers to improve early detection. #lcsm #ctDNA #lungcancerscreening
1
113
#MaTOS26 Day 1 Dr @jdoningtonmd @UofC starts the meeting w a great discussion on the challenges of lung cancer screening! 20 years after the first I-ELCAP 🫁 screening publication, we screen only ~24% of eligible individuals, and annual adherence remains below 50%. How do we close the gap? Better educate primary care, raise public awareness, and simplify the screening process! #LungCancerScreening #LCSM
1
103
Good morning from the #MaTOS26 Thoracic Summit in beautiful Half Moon Bay, CA! Grateful to @LuisRaezMD @edgardo_ny @ReckampK @christine_lovly for the invitation and for bringing together such an outstanding program!
1
17
457
The holidays are especially hard for patients, caregivers, and those grieving the loss of a loved one to cancer — as I am. Grateful for this webinar and efforts to acknowledge grief and create space to talk about it. ❤️ 👇👇
Grief can feel especially heavy during the holidays. A season often associated with celebration and togetherness can also bring longing and memories of loved ones. Our Center for the Advancement of Bereavement Care invites anyone grieving a loss, along with those supporting them, to join Wendy Lichtenthal for Coping with Grief During the Holidays. This free webinar will explore ways to make space for grief during holiday gatherings and traditions. Register: spr.ly/6015BybcCJ.
3
1
10
465
Dr. Estela Rodriguez retweeted
Excited to hear from expert thoracic oncology specialists at #MaTOSLung including our chairs @LuisRaezMD @EddieSantosMD @ReckampK @christine_lovly - lots to discuss this year!
4
1
11
733
Dr. Estela Rodriguez retweeted
Great talk by Dr. @ChristianRolfo on ctDNA MRD in early-stage NSCLC at #MaTOS2026. A strong prognostic biomarker. Ongoing questions remain: sensitivity (improved over time), CNS-only recurrence, and, critically, whether MRD-guided early intervention improves outcomes.
4
6
263
Dr. Estela Rodriguez retweeted
🚨 ESMO 2026 UPDATE: The treatment landscape of oncogene-driven NSCLC is changing! 🫁 New ESMO Living Guideline recommendations bring several important updates: 🔹 EGFR: Amivantamab + chemotherapy after osimertinib; Dato-DXd in later lines. 🔹 ALK: Lorlatinib preferred, especially with brain metastases. Ensartinib added as a 1L option. 🔹 ROS1: Taletrectinib and zidesamtinib enter treatment algorithms. 🔹 HER2 TKD mutations: Zongertinib or sevabertinib recommended in 1L. 🔹 EGFR exon20ins: Sunvozertinib after platinum chemotherapy. 🔹 NRG1 fusion: Zenocutuzumab after prior therapy. 🔹 High cMET overexpression: Telisotuzumab vedotin after 1L treatment. 💡 The big shift: Molecular profiling is increasingly important not just at diagnosis, but also at progression. 📖 Annals of Oncology, 2026 | Hendriks et al. @esmo_open @myesmo @asco @oncoalert #NSCLC #LungCancer #PrecisionOncology #ESMO26 Full paper link in comment below ⬇️.
1
36
92
5,202
Dr. Estela Rodriguez retweeted
Great questions regarding FDA decision making process. For better or worse, at least we should expect FDA to show consistency. The current tsunami of China-only or China-mainly or China-plus submissions is unprecedented, requiring consistency rather than trial by trial decisions.
One of the reasons why @FDA rejected Ivonescimab approval claim is that 93 % events occur in China. I have two questions 1- what is the cut off for events to occur in USA for USFDA to consider that data as good enough? Is there a number? 40 % , 50 % , 60 % ? 2 - Guess this trial and tell me how usfda will react to its results ? It has only 39 pts out of 602 ( 6.4 % ) from USA and in pre specified subset analysis they dont do well ( see the graph on right ) Hint - trial got maximum applause at #esmo26 . The slide is from our upcoming OncoWisdom webinar on 20 th November to discuss esmo26 key data . @Timothee_MD @StephenVLiu @JacobPlieth @KolPulseAI @NeilVasan @JackWestMD
3
20
2,320
A new wave of hope is transforming pancreatic cancer care at Sylvester. In recognition of Pancreatic Cancer Awareness Month, Sylvester's Art Is Medicine gallery is unveiling a new exhibit featuring water photography that symbolizes progress in pancreatic cancer research, treatment and patient care. The exhibit celebrates the multidisciplinary team that helped 83 patients access daraxonrasib, a new pancreatic cancer treatment, through an expanded access program before its FDA approval. Sylvester researchers contributed to clinical trials evaluating the therapy, which nearly doubled median overall survival compared with standard-of-care chemotherapy in a phase 3 trial. “A tide represents movement and change, and that’s what we’re seeing in pancreatic cancer care,” said Jessica MacIntyre, D.N.P., M.B.A., APRN, who led the exhibit concept and clinical narrative. “We’re helping turn the tide through innovation, multidisciplinary care and new treatment opportunities.” Now treating more than 140 patients with daraxonrasib, Sylvester continues to advance new treatment opportunities while recognizing the dedicated teams making these breakthroughs accessible to patients. Learn more: spr.ly/6014BywdRG
2
2
248